MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/cit336

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013

The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States.

Marks Suzanne M, Cronin Wendy, Venkatappa Thara, Maltas Gina, Chon Sandy, Sharnprapai Sharon, Gaeddert Mary, Tapia Jane, Dorman Susan E, Etkind Sue, Crosby Claud, Blumberg Henry M, Bernardo John

СтатьяПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

BACKGROUND

The utility of Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) for pulmonary tuberculosis disease diagnosis in the United States has not been well described.

METHODS

We analyzed a retrospective cohort of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia, Hawaii, Maryland, and Massachusetts to assess MTD use, effectiveness, health-system benefits, and cost-effectiveness.

RESULTS

Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were M. tuberculosis-culture-positive. Eighty percent (680/848) of patients having acid-fast-bacilli-smear-positive specimens had MTD performed; MTD positive-predictive value (PPV) was 98% and negative-predictive value (NPV) was 94%. Nineteen percent (240/1292) of patients having smear-negative specimens had MTD; MTD PPV was 90% and NPV was 88%. Among patients suspected of tuberculosis but not having MTD, smear PPV for lab-confirmed tuberculosis was 77% and NPV 78%. Compared with no MTD, MTD significantly decreased time to diagnosis in patients with smear-positive/MTD-positive specimens, decreased respiratory isolation for patients having smear-positive/MTD-negative/culture-negative specimens, decreased outpatient days of unnecessary tuberculosis medications, and reduced resources expended on contact investigation. While MTD generally cost more than no MTD, incremental cost savings occurred in patients with human immunodeficiency virus (HIV) or homelessness to diagnose or to exclude tuberculosis, and in patients with substance abuse having smear-negative specimens to exclude tuberculosis.

CONCLUSIONS

MTD improved diagnostic accuracy and timeliness and reduced unnecessary respiratory isolation, treatment, and contact investigations. It was cost saving in patients with HIV, homelessness, or substance abuse, but not in others.

Для цитирования: Marks Suzanne M, Cronin Wendy, Venkatappa Thara, Maltas Gina, Chon Sandy, Sharnprapai Sharon, Gaeddert Mary, Tapia Jane, Dorman Susan E, Etkind Sue, Crosby Claud, Blumberg Henry M, Bernardo John. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013. DOI: 10.1093/cid/cit336.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.